What is the impact of catechol-O-methyltransferase (COMT) on Parkinson’s disease treatment?

Safety and efficacy of tolcapone in Parkinson’s disease: systematic review

(2021) Carlo Alberto Artusi et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Redefining the strategy for the use of COMT inhibitors in Parkinson’s disease: the role of opicapone

(2021) Peter Jenner et al.   Expert Review of Neurotherapeutics

Different Catechol-O-Methyl Transferase Inhibitors in Parkinson's Disease: A Bayesian Network Meta-Analysis

(2021) Zhaoming Song et al.   Frontiers in Neurology

The Added Benefit of Opicapone When Used Early in Parkinson's Disease Patients With Levodopa-Induced Motor Fluctuations: A Post-hoc Analysis of BIPARK-I and -II

(2021) José-Francisco Rocha et al.   Frontiers in Neurology

Effectiveness and safety of opicapone in Parkinson’s disease patients with motor fluctuations: the OPTIPARK open-label study

(2020) Heinz Reichmann et al.   Translational Neurodegeneration

Randomized, Controlled Study of Opicapone in Japanese Parkinson's Patients With Motor Fluctuations

(2020) Atsushi Takeda et al.   MOVEMENT DISORDERS

Parkinson’s Disease: From Pathogenesis to Pharmacogenomics

(2017) Ramón Cacabelos   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Opicapone as Adjunct to Levodopa Therapy in Patients With Parkinson Disease and Motor Fluctuations

(2017) Andrew J. Lees et al.   JAMA Neurology

Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial

(2016) Joaquim J Ferreira et al.   LANCET NEUROLOGY

Catechol-O-Methyltransferase Inhibitors in Parkinson’s Disease

(2015) Thomas Müller   DRUGS